Loss of the wild-type allele promotes carcinogenesis of bladder urothelial cells with p53 missense mutation

Authors:
  • TKTakashi Kobayashi
    Takashi Kobayashi
  • KMKaoru Murakami
    Kaoru Murakami

Abstract
In advanced bladder cancer cases, p53 is the most frequently altered gene. Despite missense mutation accounts for over 60% of p53 alterations while homozygous deletion (HOM) for only 5% or less, most of the previously reported mouse models are deficient of p53. Accordingly, there have been few studies addressing whether missense mutations have an advantage over HOM in bladder cancer development. Pten-deficient, Trp53-mutant (Trp53R172H/+) organoids derived from Krt5-expressing mouse urothelium (K5-mUrorganoid) were tumorigenic in athymic mice, but every formed tumors showed loss of wild-type allele of Trp53 (Trp53R172H/LOH). Both Trp53R172H/Δ and Trp53Δ/Δ K5-mUrorganoids formed tumor in athymic mice, whereas only Trp53R172H/Δ K5-mUrorganoid formed tumor even when directly inoculated in immunocompetent syngeneic mice. The absence of wild-type Trp53 was associated with upregulation of proliferative signaling, and the presence of a mutant Trp53 allele was associated with reduced intratumoral CD8+ T cells, increased CD206+ M2 macrophages, and increased Foxp3+ regulatory T cells. This study highlights the functional significance of p53 mutant LOH in bladder carcinogenesis conferring several hallmarks of cancer such as sustaining proliferative signaling and avoiding immune destruction, and provides a novel immunocompetent mouse model of urothelial carcinoma harboring p53 mutations as a novel tool for cancer immunology research.

This publication has 51 references indexed in Scilit: